147 related articles for article (PubMed ID: 33125943)
21. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
22. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
23. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
24. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
[TBL] [Abstract][Full Text] [Related]
25. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
26. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
27. The results of multigene panel sequencing in Slovak HBOC families.
Konecny M; Kosova K; Tilandyova P; Wachsmannova L; Baldovic M; Krajcovic J; Patlevicova A; Markus J; Ciernikova S
Neoplasma; 2021 May; 68(3):652-664. PubMed ID: 33724863
[TBL] [Abstract][Full Text] [Related]
28. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort.
Kraemer D; Azzarello-Burri S; Steindl K; Boonsawat P; Zweier M; Dedes KJ; Joset P; Fink D; Rauch A
Swiss Med Wkly; 2019 Aug; 149():w20092. PubMed ID: 31422574
[TBL] [Abstract][Full Text] [Related]
32. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract][Full Text] [Related]
33. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and Spectrum of
Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
[TBL] [Abstract][Full Text] [Related]
35. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
39. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
40. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
